Stockholm, Sweden, December 5, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD)[1]. Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates …
